MAZE earnings date and last-quarter result: next report 2026-08-11, last quarter beat, P/E -10.36. Updated 2026-07-23.
Maze Therapeutics (MAZE) Research Hub
Maze Therapeutics (MAZE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 31.07 USD (+0.19%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.36, market cap 1.57B. This hub links to the full technical, earnings and options research available for MAZE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 31.07 USD (+0.19%) |
| 52-week range | 21.95 USD – 33.49 USD |
| Trend regime | Range |
| 14-day RSI | 69.6 (Bullish) |
| Trailing P/E | -10.36 |
| Market cap | 1.57B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for MAZE
Covered Call on MAZE: how it works, illustrative setup around the real 31.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MAZE: how it works, illustrative setup around the real 31.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MAZE: how it works, illustrative setup around the real 31.07 USD price, max profit/loss, breakeven and when to use it. Educational.
MAZE technical analysis: range, last 31.07 USD, RSI 69.6, 52w range 21.95 USD–33.49 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is MAZE in?
Maze Therapeutics (MAZE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MAZE in an uptrend or downtrend?
As of 2026-10-26, MAZE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MAZE's trailing P/E ratio?
MAZE's trailing P/E is -10.36, with a market cap of 1.57B. See the earnings research page for full valuation detail.
When does MAZE next report earnings?
MAZE is next scheduled to report earnings on 2026-08-11.